Lisa Alderson (@LisaAlderson2) header
Lisa Alderson (@LisaAlderson2) profile picture

Mom, cardiologist, Cardinals and Billikens fan, avid watcher of MO politics. Opinions/tweets are my own.

Joined June 2012
Photo by Lisa Alderson (@LisaAlderson2)Photo by Lisa Alderson (@LisaAlderson2)Photo by Lisa Alderson (@LisaAlderson2)Photo by Lisa Alderson (@LisaAlderson2)Photo by Lisa Alderson (@LisaAlderson2)Photo by Lisa Alderson (@LisaAlderson2)Photo by Lisa Alderson (@LisaAlderson2)Photo by Lisa Alderson (@LisaAlderson2)Photo by Lisa Alderson (@LisaAlderson2)
Lisa Alderson retweeted
At least 10% of the population has a significantly elevated Lp(a) above 50 mg/dL (~125 nmol/L), which carries an increased risk of atherosclerotic cardiovascular disease. While we've known that for decades, we've never had a drug to treat it. There are 5 programs in advanced trials (Table below, 3 in phase 3, pivotal, CV outcomes as endpoint). We may see the results for the first drug (pelacarsen) soon, by end August, and FDA approval is expected in 2027. This likely represents a major advance for preventing heart disease, adding to the first oral PCSK9 blocker approved this week.
45
207
13
947
91,760
Lisa Alderson retweeted
The Crochetage sign & ostium secundum ASD. ● Crochetage sign = Notching of the R wave at the apex of the R wave in the inferior leads on ECG. ● Seen in leads II, III, and aVF ● The notch resembles a “crochet hook”, which is why it is called crochetage (French for crochet). 》ECG Appearance ● Notched R wave in inferior leads (II, III, aVF). ● The notch is typically at the peak of the R wave. ● Often associated with incomplete right bundle branch block. 》Diagnostic Value ● Highly suggestive of secundum ASD. ● Specificity increases when present in all three inferior leads. ● The sign may disappear after ASD closure (surgical or device closure). 》Clinical Pearls ● Crochetage sign + incomplete RBBB → think ASD. ● Persistence of the sign may indicate residual shunt after closure.
1
44
168
6,867
Lisa Alderson retweeted
Interesting bubble #echofirst image What does it demonstrate? What is the likely diagnosis? #POCUS #Nephmadness Source: J Cardiothorac Surg. 2024;19(1):175. doi: 10.1186/s13019-024-02709-8.
12
38
2
140
30,108
Lisa Alderson retweeted
📍A practical guide to the management of dyslipidaemia 👉Dyslipidaemia: from guidelines to real life (and why we’re still failing) 1️⃣LDL-C remains causal for ASCVD — dose- and time-dependent. Lower and earlier is better. No credible safety signal at very low levels. 2️⃣Targets are clear, achievement is not: most high- and very-high risk patients still miss guideline LDL-C goals in daily practice. 3️⃣Risk ≠ LDL-C alone: ApoB, remnant cholesterol, and lipoprotein(a) explain a large part of residual risk. 4️⃣Lp(a) matters: measure it at least once in every patient. Levels >50 mg/dL (>125 nmol/L) are a true risk enhancer. 5️⃣Risk modifiers change decisions: chronic inflammatory diseases, CKD, HIV, family history, and imaging findings should up-classify risk. 6️⃣Lifestyle is mandatory—but insufficient for most high-risk patients. Supplements? No evidence, no benefit. 7️⃣Statins first, but not alone: early combination therapy (statin + ezetimibe ± bempedoic acid) should be the norm, not the exception. 8️⃣PCSK9 inhibition works: robust LDL-C lowering and outcome benefits, even in high-risk primary prevention. 9️⃣Post-ACS paradigm shift: strike early and strong with upfront combination therapy. Delay costs events. 🔟Bottom line: combination lipid-lowering can get >90% of patients to target—if we actually use it. 👉 Guidelines are not the problem. Implementation is. 🔗Open Access doi.org/10.1007/s00392-025-0… @society_eas @SpringerNature
13
134
3
360
19,195
LV Thr unusual since preserved LV contractility. Angiosarcoma? 2 different patients with similar multiple masses in LA. In both cases it turned out to be an angiosarcoma #echofirst
1
19
74
5,892
Etiology and #anticoagulation efficacy in patients with left ventricular thrombus: new original evidence in #EHJPharmacotherapy 💊🔍 ow.ly/sK0T50XViM1 @EditorEHJCVP @FeliceGragnano #EHJPharmacotherapy
1
41
3
110
9,325
Beyond the Statin: Navigating the New Frontier of Heart Health 🚀❤️ The "statin-only" era has officially evolved! A 2025 appraisal in JACC: Advances reveals that while statins remain the foundational therapy, we've entered a "Post-Statin Era" defined by a massive, personalized toolkit to slash cardiovascular risk. The 2026 Game-Changers 🧬 The PREVENT Revolution: New PREVENT equations are replacing older models to offer more accurate, race-free risk estimation. However, they often yield lower risk scores, requiring clinicians to use sharper judgment to ensure high-risk patients aren't overlooked. The Power of "Plus": Doubling a statin dose only adds about 6% more LDL-C lowering. But adding non-statin therapies like ezetimibe, PCSK9 inhibitors, or bempedoic acid can reduce levels by an additional 20–50%! The CAC "Tie-Breaker": Coronary Artery Calcium (CAC) scoring is now the ultimate tool for personalizing care. 📸 CAC = 0: May allow for the safe deferral of statins in many patients. CAC ≥ 300: This is considered "Very High Risk"—a danger level similar to having already survived a heart attack. Precision for Every Population 🌍 The findings emphasize that "average" care isn't enough: South Asian Populations: Often face more aggressive disease at lower "traditional" risk levels and may benefit from earlier screening. Younger Adults: 10-year scores often hide a massive lifetime risk; we must look at the 30-year horizon. Women's Health: Managing severe cholesterol during pregnancy requires a careful balance using safe options like bile acid sequestrants. Heart health in 2026 is no longer about a single pill—it’s about a strategy tailored to your unique biology. 🤝✨ #Cardiology #HeartHealth #MedEd #LipidManagement #PostStatinEra #PreventiveMedicine
2
87
1
276
17,778
This is impressive CV risk reduction with Tirzepatide vs Semaglutide The fact that we have these incretin therapies available is a game changer. Now we just have to make them accessible and cheaper #GLP1RA #weightloss #CVRisk #CVPrev #cardiotwitter
Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial ow.ly/5bL850XiWTZ @ehjopen @SaDeRosa78 @ProfMagnusBack @SABOURETcardio #EHJOpen
8
41
3
220
31,108
#Sharing is learning 25yo 👩🏻 Right sided enlargement What is your #diagnosis? 📷 #whyCMR #cardioTwitter ⁦ @HaticeKGunsel
2
10
1
33
8,291
#REFINE_ICD trial Efficacy of ICD therapy in higher risk post-MI pts with LVEF: 35-50% & impaired autonomic tone & abnormal cardiac repolarization on a Holter (TWA/HRT) ⛔️ No benefit #ESCCongress2025 @escardio #ESCCongress @ESCardioNews
1
1
222
Prophylactic ICD therapy did not 🚫 reduce mortality in patients with a prior MI, persistent moderate LV systolic dysfunction and abnormal ECG markers🚩, based on findings from REFINE-ICD presented at #ESCCongress. ➡️ Read the news story: bit.ly/4n2InNP
1
6
14
2,226
Lisa Alderson retweeted
I did not know this 👇🏻
When should you measure Lp(a) post MI? It goes down then up in the first couple of weeks post MI so check it on arrival and then at 30 days @society_eas @BNordestgaard @escardio #ESC2025
6
13
73
12,172
Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes: @NEJM 🥸 The slow decline of aspirin: #ESCCongress2025 😱 Here is the summary of the NEO-MINDSET Trial 👇👇👇
9
127
4
518
80,522
Lisa Alderson retweeted
🌟 HYPERTENSION - Simplified Treatment Algorithm 🔸️Use 𝗔 𝗕 𝗖 𝗗 A - ACEi/ARBs B - Beta Blockers C - CCBs D - Diuretics ( Thiazide)
6
108
2
537
58,507
Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines (EMPACT) EMPACT (EMPAgliflozin in prevention of chemotherapy-related CardioToxicity) study is a randomized, multi-center, placebo-controlled, double-blind trial to evaluate efficacy of empagliflozin in prevention of left ventricular (LV) dysfunction in patients receiving high cumulative doses of anthracyclines clinicaltrials.gov/study/NCT…
3
39
2
136
8,481
Lisa Alderson retweeted
🫀 #CardioNugget: Unroofed Coronary Sinus An unroofed coronary sinus (URCS) is a rare anomaly where part of the wall between the CS and LA is missing, allowing oxygenated blood from LA to shunt into the CS, then RA ➡️ mimicking an ASD! 💡 Key clues: Dilated coronary sinus on echo Often associated with a persistent left SVC #CardioNuggets #CardioTwitter #MedEd
3
30
136
7,524